JPY 6550.0
(0.0%)
Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 38.89 Billion | 34.3 Billion | 31.66 Billion | 34.07 Billion | 31.29 Billion |
Cost of Revenue | 24.35 Billion | 22.7 Billion | 20.94 Billion | 22.77 Billion | 20.55 Billion |
Gross Profit | 14.53 Billion | 11.6 Billion | 10.72 Billion | 11.3 Billion | 10.74 Billion |
Operating Expenses | 8.28 Billion | 7.09 Billion | 6.64 Billion | 6.71 Billion | 6.31 Billion |
Selling, General and Administrative Expenses | 7.93 Billion | 6.77 Billion | 6.32 Billion | 6.54 Billion | 508.83 Million |
Research and Development Expenses | 79 Million | 107 Million | 63 Million | 104 Million | 92.94 Million |
Other Expenses | 272 Million | 27 Million | 24 Million | 33 Million | -163.78 Million |
Cost and Expenses | 32.64 Billion | 29.8 Billion | 27.59 Billion | 29.49 Billion | 26.87 Billion |
Operating Income | 6.24 Billion | 4.5 Billion | 4.07 Billion | 4.58 Billion | 4.42 Billion |
Interest Expense | - | - | - | - | - |
Income Tax Expense | 1.63 Billion | 1.44 Billion | 1.37 Billion | 1.33 Billion | 1.27 Billion |
Earnings before Tax | 6.31 Billion | 4.61 Billion | 4.4 Billion | 4.65 Billion | 4.46 Billion |
Net Income | 4.67 Billion | 3.16 Billion | 3.02 Billion | 3.32 Billion | 3.18 Billion |
Earnings Per Share Basic | 585.76 | 395.48 | 378.40 | 415.28 | 397.76 |
Earnings Per Share Diluted | 585.76 | 395.48 | 378.40 | 415.28 | 397.76 |
Weighted Average Shares Outstanding | 7.97 Million | 8 Million | 8 Million | 8 Million | 8 Million |
Weighted Average Shares Outstanding (Diluted) | 7.97 Million | 8 Million | 8 Million | 8 Million | 8 Million |
Gross Margin | 0.37 | 0.34 | 0.34 | 0.33 | 0.34 |
EBIT Margin | 0.17 | 0.14 | 0.13 | 0.14 | 0.15 |
Profit Margin | 0.12 | 0.09 | 0.10 | 0.10 | 0.10 |
EBITDA | 6.66 Billion | 4.89 Billion | 4.46 Billion | 4.81 Billion | 4.62 Billion |
Earnings Before Tax Margin | 0.16 | 0.13 | 0.13 | 0.13 | 0.14 |
Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
---|---|---|---|---|---|---|
Revenue | 8.43 Billion | 6.55 Billion | 13.87 Billion | 38.89 Billion | 9.43 Billion | 8.38 Billion |
Cost of Revenue | 4.97 Billion | 3.99 Billion | 8.38 Billion | 24.35 Billion | 5.48 Billion | 5.46 Billion |
Gross Profit | 3.46 Billion | 2.55 Billion | 5.48 Billion | 14.53 Billion | 3.95 Billion | 2.92 Billion |
Operating Expenses | 1.91 Billion | 1.78 Billion | 3.15 Billion | 8.28 Billion | 1.77 Billion | 1.71 Billion |
Selling, General and Administrative Expenses | 1.91 Billion | 1.78 Billion | 2.8 Billion | - | 1.77 Billion | 1.71 Billion |
Research and Development Expenses | - | - | 79 Million | - | 15 Million | 20 Million |
Other Expenses | - | 1 Million | -14 Million | 16 Million | 6 Million | 15 Million |
Cost and Expenses | 6.88 Billion | 5.78 Billion | 11.54 Billion | 32.64 Billion | 7.26 Billion | 7.17 Billion |
Operating Income | 1.54 Billion | 769 Million | 2.32 Billion | 6.24 Billion | 2.17 Billion | 1.21 Billion |
Interest Expense | - | - | - | - | - | - |
Income Tax Expense | 496 Million | 266 Million | 364 Million | 1.63 Billion | 685 Million | 402 Million |
Earnings before Tax | 1.57 Billion | 833 Million | 2.28 Billion | 6.31 Billion | 2.2 Billion | 1.24 Billion |
Net Income | 1.07 Billion | 567 Million | 1.92 Billion | 4.67 Billion | 1.51 Billion | 845 Million |
Earnings Per Share Basic | 135.53 | 71.24 | 241.43 | - | 190.52 | 105.94 |
Earnings Per Share Diluted | 135.53 | 71.24 | 241.43 | - | 190.52 | 105.94 |
Weighted Average Shares Outstanding | - | 7.95 Million | 7.96 Million | 7.97 Million | 7.95 Million | 7.97 Million |
Weighted Average Shares Outstanding (Diluted) | - | 7.95 Million | 7.96 Million | 7.97 Million | 7.95 Million | 7.97 Million |
Gross Margin | 0.41 | 0.39 | 0.40 | 0.37 | 0.42 | 0.35 |
EBIT Margin | 0.19 | 0.13 | 0.17 | - | 0.23 | 0.14 |
Profit Margin | 0.13 | 0.09 | 0.14 | 0.12 | 0.16 | 0.10 |
EBITDA | 1.58 Billion | 872.75 Million | 2.38 Billion | - | 2.18 Billion | 1.21 Billion |
Earnings Before Tax Margin | 0.18 | 0.12 | 0.17 | 0.16 | 0.23 | 0.15 |
FSA
TAER
AA
2804
MSM
HSHPO